Background: Hypertension is considered the most prevalent cardiovascular disorder and a significant public health problem. A functional food that could potentially impede progression into a hypertensive state in pre-hypertensive individuals is of significant interest to clinicians and consumers. In vitro and animal studies suggest the presence of potential ACE inhibitory dairyand soy-derived peptides. Very few human-based research studies have been conducted to investigate the blood pressure lowering and/or ACE-inhibitory effects of whey and soy protein hydrolysates in humans. This pilot study tested the acute effects of 20g doses of whey and soy hydrolysates in pre-hypertensive, overweight men and postmenopausal women on serum ACE activity and blood pressure.
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INTRODUCTION:
The renin-angiotensin-aldosterone system (RAAS) primarily increases blood pressure by producing the vasoconstrictor angiotensin II, facilitated by angiotensin-converting enzyme (ACE). Researchers have found antihypertensive potential in dairy-derived peptides [1] [2] [3] [4] [5] [6] . The development of functional foods that may prevent hypertension in pre-hypertensive individuals is intriguing. We investigated the effects of an acute dose of whey-and soy-derived bioactive peptides on ACE activity and blood pressure in pre-hypertensive, overweight men and postmenopausal women.
METHODS:
Study Overview: This randomized, single-blind cross-over study compared whey protein hydrolysate (WPH), whey protein isolate (WPI), soy protein hydrolysate (SPH), soy protein isolate (SPI), and casein at 20g doses, an amount expected to elicit a biological effect based on a study reporting significant blood pressure reduction in humans consuming 20g WPH for six weeks [7] . To determine acute effects, measurements were taken up to 180 minutes posttreatment. See Figure 1 for study design. Testing Visits: Subjects arrived to the DCRU by 0700 fasted from 1900 the day before and were instructed to lie supine with one pillow beginning 30 minutes before baseline, after which blood pressure assessment and blood draw for ACE activity were performed. Subjects consumed one of the five randomly assigned treatments, after which the Time 0 was marked. Blood sampling occurred at 30-minute intervals from Time 0 to 180 minutes, determined from a small preliminary study where nine subjects received 20g of one of the treatments and blood collection occurred at 15-and 30-minute intervals up to 300 minutes.
Controlled Diet

Pre
Controlled Diet: DCRU Nutrition Services designed a controlled diet to meet individual energy needs that was whey-, soy-, and dairy-free, providing 1g of sodium and 1.5g of potassium per 1,000 calories. All meals were provided and subjects were to report off-plan intake on food records and to return remains.
Production of hydrolysates:
Davisco Foods International, Inc. (Eden Prairie, MN) provided the WPI (BiPro) and WPH (Biozate 1). Archer Daniels Midland Company provided defatted soy flour samples (Decatur, IL). Minimally heat-treated and defatted soy flour was used to prepare SPI following methods outlined by Tsumura et al [8] . Produced SPI was used to prepare SPH following selective hydrolysis with papain, mainly targeting hydrolysis of the β-conglycinin component [9] .
Production of treatment cookies: Whey-derived peptides are typically delivered in beverages [3, 7] . The insolubility of SPH in liquid and desire for optimal palatability influenced our decision to utilize the unique delivery form of a cookie. Twenty grams of the protein were divided into four cookies (Table 2 ) baked in a conventional oven at 449.7 K for seven minutes. In vitro ACE inhibition of hydrolysates before and after heating: ACE inhibitory activity measurements of the hydrolysates were conducted, in triplicate, following the assay outlined by Otte et al [10] and Shalaby et al [11] using FA-PGG as substrate, with modifications adapted from Margatan et al [9] . The influence of thermal or pH instability on bioactivity or digestive survivability of peptides after baking is uncertain; therefore, SPH ACE inhibition was tested post thermal treatment similar to cookie baking conditions. In vitro inhibition was unaffected by heat treatment (data published elsewhere) [9] . Plasma ACE Activity Assay: At each time point, blood was collected (5mL), clotted, held at room temperature, and cold spun at 2091 RCF for 10 minutes. Serum (1mL) was aliquotted into cryogenic vials in duplicate, flash frozen with dry ice and alcohol, and stored at 210.8 K before shipment on dry ice to ARUP Laboratories (Salt Lake City, UT).
Statistical Analysis: Area under the curve (AUC) was calculated for each subject and treatment for ACE activity and systolic blood pressure (SBP) from baseline to 180 minutes ((Phoenix WinNonlin 6.3, Mountain View, CA, USA)). Because in vivo digestion of WPI, SPI, and casein could yield ACE-inhibitory peptides, differences across all treatments for both endpoints were evaluated using repeated measures ANOVA with post-hoc comparisons ((GraphPad InStat version 3.10 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com)). Significance was set at p <0.05.
RESULTS:
In vitro ACE inhibition of the SPH and WPH samples were similar, (IC 50 of 0.177mg SPH protein/mL, 0.200mg WPH protein/mL [9] and fell within the reported range of IC 50 values for ACE inhibitory peptides (0.046-0.930 mg protein/mL) [12] [13] [14] [15] [16] . No adverse events were reported, treatments were tolerated, and compliance was good. However, logistical challenges with study continuation encouraged an interim analysis of data from the first four subjects. A lack of significant differences between treatment proteins on either endpoint halted subject recruitment. Data from these four subjects are presented. See Table 3 for subject characteristics. Graphical representation of mean ACE activity ( Figure 2 ) and SBP ( Figure 3 ) over time, illustrate the variability among treatments. 
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DISCUSSION:
Differences between treatments were undetected and no treatment lowered SBP or inhibited ACE to any observable degree. Strengths include use of a cross-over design, inclusion of in vitro ACE activity measurements, and a diet controlling potassium and sodium for consistency with close monitoring of compliance. However, only an acute dose of 20g was tested. This amount may be insufficient; studying the effects of multiple doses, or chronic dosing, over time would be more informative. Additionally, subjects were either mildly pre-hypertensive or normotensive; ACE-inhibitory potential may be more evident in pronounced hypertension. Other RAAS proteins were unevaluated to support or negate the proposition of ACE inhibition as the mechanism for reduced blood pressure. Finally, peptides were delivered in baked cookies. While heat stability in ACE-inhibitory activity was confirmed, stability to increased pH (potentially following added sodium bicarbonate and baking powder) is unknown. Although uncertain, pH and heat synergism and reactions occurring in heat conditions between proteins and reducing sugars, like the Maillard reaction, may influence bioactivity; these were not directly evaluated. Work is needed to determine optimal delivery to humans.
In conclusion, an acute dose of 20g of either SPH or WPH when delivered in a uniquely formulated cookie did not reduce SBP or ACE activity. Discrepancies between in vitro ACE inhibition by SPH and WPH and inadequate in vivo evidence warrant further research, particularly to determine peptide bioavailability for optimal dosing to achieve biological effects.
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